RESEARCH-USE BIOSIMILAR ANTIBODY

Glembatumumab

Antibody-drug conjugate · IgG2

GPNMBIgG2RUO

Glembatumumab is a fully human IgG2 monoclonal antibody directed against the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. Glembatumumab can be coupled to the microtubule inhibitor monomethyl auristatin E to form glembatumumab vedotin. Glembatumumab vedotin is an antibody-agent coupling (ADC) with antitumor activity.

TARGETGPNMB
YAntibody-drug conjugate
CATALOGSC-BS-508
CATALOG NUMBERSC-BS-508
MOLECULAR WEIGHTApprox. 145.56 kDa
PRODUCT FORMATAntibody-drug conjugate

A research-use configuration for comparative antibody studies

Glembatumumab is a fully human IgG2 monoclonal antibody directed against the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. Glembatumumab can be coupled to the microtubule inhibitor monomethyl auristatin E to form glembatumumab vedotin. Glembatumumab vedotin is an antibody-agent coupling (ADC) with antitumor activity.

Glembatumumab is a recombinant research-use antibody directed against GPNMB.

START A CONVERSATION

Tell us about your research goals.

For quotes, sample requests or technical support, start with your target and experimental context.

Contact StellaCyte